Profhilo

Profhilo is a hyaluronic-acid-based bio-remodeller administered as a clinical injectable. The published mechanism in dermatology literature describes it as a bio-stimulator that supports collagen and elastin biology over months rather than as a volume-replacing dermal filler. It is delivered as a structured schedule of clinical sessions in suitable adult candidates following a clinical assessment. At Delhi Derma Clinic, the bio-remodeller is treated as a clinical injectable with screening, consent, sterile technique, and adverse-event monitoring rather than as a "skin facial" or "beauty treatment". It is not appropriate for every adult; the suitability assessment at the first visit determines fit.

No. Bio-remodellers and dermal fillers are different categories of injectable with different mechanisms, indications, and risk profiles. Dermal fillers are designed to replace volume in defined facial zones (cheeks, lips, nasolabial folds, jawline) using cross-linked hyaluronic acid that occupies space at the injection point. Bio-remodellers are not designed for volume replacement; the published mechanism is bio-stimulation supporting collagen and elastin biology over months. Patients seeking volume change should not use a bio-remodeller as a substitute; the consultation differentiates honestly. Filler conversations are a separate framework with separate consent.

No. The framework explicitly avoids "instant glow" framing because it sets unrealistic expectations and miscalibrates the consent for a clinical injectable. The published mechanism is gradual bio-stimulation supporting skin biology over months. Patients seeking single-session dramatic glow are not appropriate candidates and the consultation says so before any session is booked. Outcomes vary; the realistic frame is gradual quality change over the structured schedule and beyond, in suitable candidates with realistic expectations.

Suitable candidates are adult patients with skin-quality concerns assessed clinically as appropriate for the bio-remodeller, stable medical history without active inflammation or relevant infection in the treatment area, no allergy history relevant to hyaluronic acid or injectable preparations, willingness to engage with a structured schedule and follow-up, and acceptance of the framework that the bio-remodeller is one component within a broader plan. The first visit produces the suitability assessment in writing. Mismatched candidacy is referred or deferred honestly.

Patients with allergy to hyaluronic acid components, active facial infection or inflammation in the treatment area, active autoimmune connective-tissue conditions affecting injection safety, pregnancy or lactation, significant volume-loss expectations (a different framework — fillers — is the appropriate consideration with separate consent), patients with severe laxity expecting injectable correction, or patients with unrealistic transformation expectations. The framework refers honestly rather than running an unsuitable plan.

Bio-remodeller injection is delivered by the dermatologist in clinical conditions with appropriate sterile technique. The specific protocol — injection technique, points, depths, and per-session approach — is clinician-led and case-specific based on the published guidance and the patient's assessment. The page does not publish prescription-level protocol detail because this is a clinician-led decision rather than a self-administered or do-it-yourself framework. The consultation describes the schedule in general terms and produces consent that the patient signs before any session.

Most patients describe the injection as mildly uncomfortable rather than significantly painful. Topical numbing or other comfort measures may be used at the clinician's discretion. The framework discusses comfort honestly at consent rather than minimising it; comfort experience varies between patients, and the first session calibrates against the individual's response.

Outcomes vary by patient and by suitability. The published evidence base describes the bio-stimulation effect as supporting collagen and elastin biology over months; the specific duration of perceived skin-quality change differs between patients and depends on baseline skin quality, lifestyle anchor, and other factors. Continuation, maintenance, or pause decisions are made in consultation rather than auto-rolled. The framework is honest that without continuation the trajectory returns toward baseline as natural skin biology continues.

Common post-injection effects include transient localised swelling, bruising at injection points, mild redness, and tenderness for several days. Less common adverse events include persistent bumps, nodule formation, infection at injection points, and very rare vascular events. The framework discusses each of these openly at consent — incidence range, recognition pattern, and what to do if the patient notices any unusual symptom. Prompt clinical review is part of the operating standard if anything unexpected appears; the patient is not asked to wait for the scheduled review window if a concerning symptom develops.

Hyaluronic-acid-based injectables generally have a low post-procedure pigmentation risk in Fitzpatrick III–V patients when administered in suitable candidates with appropriate clinical technique. Friction, sun exposure during recovery, and aggressive topicals around sessions can shift the picture; the aftercare framework reflects Indian-skin considerations. The clinical safety review (allergy screen, sterile technique, follow-up) is consistent across skin types; the Indian-skin-aware aftercare runs alongside.

In selected suitable adults, combined plans that include the bio-remodeller alongside energy-based collagen-remodelling tools may produce a more integrated skin-quality outcome than either alone. Combination is suitability-assessed; the cadence is engineered so each component respects its own interval. The framework is conservative — combined plans are for selected adults rather than as a default, and the consultation determines fit. Combining the bio-remodeller with other injectables (particularly volumising fillers) is a separate clinical conversation.

Bio-remodeller hyaluronic-acid injectables are regulated medical products in many jurisdictions including India, with manufacturing standards and clinical-use frameworks defined by the relevant regulatory authorities. The clinic's framework follows the regulatory and clinical guidance for use; specific regulatory status and product-level detail is the manufacturer's and regulator's domain rather than the patient-facing page. Patients with regulatory or product-specific questions are welcome to raise them at the consultation.

Bio-remodeller injection is a clinical procedure performed by a dermatologist with screening, consent, sterile technique, and adverse-event monitoring. It is not a "skin booster facial", a salon-style intervention, or a beauty treatment. Patients who arrive expecting a single-session glow or a beauty-treatment framing are not appropriate candidates; the framework is clinical and the consent reflects that. Some marketing in the broader market frames injectables in beauty-treatment language; the Delhi Derma Clinic framework explicitly avoids that conflation because it miscalibrates the consent and the patient's expectations.

In suitable candidates with realistic expectations, the change is gradual and integrated, which generally reads as a subtle skin-quality shift rather than as an obvious procedure. Patients sometimes report that friends and family ask whether they have changed their skincare or slept better rather than identifying a procedure. The framework prioritises subtle, gradual outcomes; patients seeking obvious dramatic change are not appropriate candidates for the bio-remodeller alone.

No. Non-urgent injectable work is deferred until after delivery and the post-lactation window. Pregnancy and lactation are physiological states with their own safety considerations; the framework does not run elective procedural plans during these windows.

A history of easy bruising is reviewed at the medical screening conversation. Anticoagulant medication, antiplatelet therapy, certain supplements, and recent dental procedures all increase bruising risk and may shift the timing or protocol. The framework does not stop care universally for a bruising history; it adjusts protocol and consent accordingly. Patients with significant bruising tendency or bleeding disorders may need medical clearance before injection.

Consultation starts from ₹1,999*. Beyond consultation, bio-remodeller cost depends on suitability assessment, the per-session structure, the structured-schedule arrangement, whether combined-plan adjuncts are part of the case, and the continuation decision after the structured schedule. The pricing is per-session rather than as a flat package; this protects the patient from forced commitment beyond clinical suitability. The written quote at consultation makes the structure transparent. Verified procedural prices are not published on this page; cost factors are listed; the actual quote is produced in writing at the consultation.

Bio-remodeller case photography used in the clinical record is consent-based, captured under standardised conditions, and represents the actual case shown rather than a promised outcome for any other patient. Some patients request to see representative case photographs at consultation; the clinic shares those with patients who attend the consultation. The framework explicitly avoids using photographs to imply fixed-outcome promises for a regulated injectable category; outcomes vary, and the realistic-range conversation is the consent step rather than the photograph being the conversation.

Persistent or escalating symptoms — severe pain, escalating redness or warmth, vision change, unusual swelling pattern, persistent bumps that are not resolving, signs of infection — warrant prompt clinical review rather than waiting for the scheduled review window. The framework provides access to clinical review when the patient notices anything unexpected; commercial considerations do not gate the safety review. Recognition of warning signs is discussed at consent so the patient knows what to look for.

Consent is a structured part of the framework rather than a checkbox. The consultation describes the published mechanism, the suitability assessment outcome, the schedule in general terms, the realistic outcome framing, the risks (common, less common, rare), the recovery framework, and the cost structure. The patient is given the consent document and time to read it before the first session; questions are encouraged. Consent without explicit risk discussion is incomplete; the framework treats this as part of the operating standard rather than a formality.

Yes — the bio-remodeller framework specifically encourages this pattern because suitability for an injectable is not a same-room decision. The consultation produces a structured written assessment with the suitability outcome, the schedule in general terms, the risks discussion, and the per-session cost framing. Many patients take the assessment home to read in calm conditions, raise questions through follow-up correspondence, and return ready when ready. The clinical injectable framework explicitly avoids in-the-room commitment pressure; the consent sequence is designed for considered decision rather than reactive booking.

No. Outcomes vary by patient and by suitability. Some adults in the suitable candidacy band notice gradual skin-quality change across the structured schedule; others notice more limited change. Patients in the unsuitable candidacy band are referred honestly to the right pathway. The framework is explicit that the bio-remodeller is not a universal solution and that the consultation's job is to determine whether it is the right component for the specific case rather than to default-include it.

Patients can stop the structured schedule at any session if they choose. The framework is honest that the structured schedule produces the response curve described in the published evidence base; stopping early may produce less response than completing the schedule. Some patients stop because the response is not what they hoped for; the consultation review at that point may suggest a different pathway. The framework does not pressure continuation; the per-session structure protects the patient.

No headline procedural prices for the bio-remodeller are published on this page or elsewhere on the Delhi Derma Clinic site. Cost factors are listed; the actual per-session quote is produced in writing at the consultation. This is a deliberate framework decision — published procedure prices for a clinical injectable can encourage commercial decisions ahead of clinical suitability decisions. The framework prioritises suitability assessment first and per-component pricing in writing afterwards, rather than headline figures designed for online comparison shopping.

The bio-remodeller is one component within a broader routine rather than a substitute for daily skincare. A consistent daily routine — sun protection appropriate to Indian-skin types, gentle cleansing, hydration, antioxidant support, retinoid escalation where appropriate under clinical guidance — provides the baseline that any procedural plan builds on. Patients with a strong routine baseline tend to derive more from the bio-remodeller component than patients without that baseline. The first visit reviews the routine alongside the procedural assessment so the two integrate rather than conflict; some patients benefit more from improving the routine first and revisiting the bio-remodeller question later. The framework explicitly does not treat the bio-remodeller as a routine replacement; an injectable cannot substitute for the protective and supportive work that consistent daily skincare provides at the cellular and barrier level. Patients sometimes ask whether the bio-remodeller "lets them skip" daily routine; the honest answer is no, and the consultation makes that clear before any session is booked.

The decision is suitability-led and case-specific. Patients with primarily texture or post-acne quality concerns route to fractional or microneedling-based pathways; patients with mild laxity-and-quality combined concerns may route to combined energy-based plans; patients with mild crepiness and elasticity-perception concerns where the case profile fits the bio-remodeller indication route to the bio-remodeller suitability assessment. The framework deliberately avoids a default-recommendation approach — every adult who walks in does not automatically become a bio-remodeller candidate. The first visit's job is to find the right pathway rather than route everyone toward the same intervention. The clinic actively flags cases where the bio-remodeller is not the right answer rather than running the assessment as a sales-funnel exercise; some patients leave the consultation with a different plan, and that is the framework working correctly.